NXERA PHARMA UK LIMITED

Active Cambridge

Research and experimental development on biotechnology

185 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
N

NXERA PHARMA UK LIMITED

Research and experimental development on biotechnology

Founded 4 Jun 2007 Active Cambridge, United Kingdom 185 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology

Previous Company Names

HEPTARES THERAPEUTICS LIMITED 4 Jun 2007 — 2 Apr 2024
Accounts Submitted 1 Aug 2025 Next due 30 Sept 2026 4 months remaining
Confirmation Submitted 9 Jun 2025 Next due 13 Jun 2026 27 days remaining
Net assets £172M £8M 2024 year on year
Total assets £232M £17M 2024 year on year
Total Liabilities £60M £9M 2024 year on year
Charges 1
1 satisfied

Contact & Details

Contact

Registered Address

Granta Park Great Abington Cambridge Cambridgeshire CB21 6DG

Email

info@example.com

Website

www.example.com

Full company profile for NXERA PHARMA UK LIMITED (06267989), an active life sciences and medical technology company based in Cambridge, United Kingdom. Incorporated 4 Jun 2007. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type Total Exemption Full
Next accounts 31 December 2025
Due by 30 September 2026 9 months

Balance Sheet & P&L (2014–2024)

Cash in Bank

£113.41M

Decreased by £18.77M (-14%)

Net Assets

£172.42M

Increased by £7.74M (+5%)

Total Liabilities

£59.60M

Increased by £9.42M (+19%)

Turnover

£78.20M

Increased by £49.89M (+176%)

Employees

185

Increased by 2 (+1%)

Debt Ratio

26%

Increased by 3 (+13%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
Dec Year End
2023
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 6

Investors (10)

Investor NameInvestor SinceParticipating Rounds
Investor 10Aug 2007Seed
Investor 6Feb 2009Series B, Series A
Investor 8Feb 2009Series A

Officers

Officers

0 active 3 resigned
Status

No officers found

No officers found

Shareholders

Shareholders (1)

Nxera Pharma Co., Ltd.
100.0%
41,640,598

Persons with Significant Control

Persons with Significant Control (0)

0 Active 3 Ceased

Fiona Hamilton Marshall

Ceased 28 Feb 2018

Ceased

Malcolm Weir

Ceased 31 Dec 2018

Ceased

Peter Jonathan Bains

Ceased 31 Dec 2018

Ceased

Group Structure

Group Structure

No group structure identified

Charges

Charges

1 satisfied

Properties

Properties

3 leasehold 3 total
AddressTenurePrice PaidDate Added
Steinmetz Building, Granta Park, Great Abington, Cambridge (CB21 6DG) SOUTH CAMBRIDGESHIRE
Leasehold-11 Dec 2018
Steinmetz Building, Granta Park, Great Abington, Cambridge (CB21 6DG) SOUTH CAMBRIDGESHIRE
Leasehold-20 Jun 2018
Land adjoining Steinmetz Building, Granta Park, Great Abington, Cambridge (CB21 6DG) SOUTH CAMBRIDGESHIRE
Leasehold-20 Jun 2018
Steinmetz Building, Granta Park, Great Abington, Cambridge (CB21 6DG)
Leasehold
Added 11 Dec 2018
District SOUTH CAMBRIDGESHIRE
Steinmetz Building, Granta Park, Great Abington, Cambridge (CB21 6DG)
Leasehold
Added 20 Jun 2018
District SOUTH CAMBRIDGESHIRE
Land adjoining Steinmetz Building, Granta Park, Great Abington, Cambridge (CB21 6DG)
Leasehold
Added 20 Jun 2018
District SOUTH CAMBRIDGESHIRE

Documents

Company Filings

DateCategoryDescriptionDocument
29 Oct 2025IncorporationMemorandum Articles
23 Oct 2025ResolutionResolutions
21 Oct 2025OfficersTermination of Matthew Joseph Barnes as director on 30 Sept 2025
21 Oct 2025OfficersAppointment of Dr Patrik Foerch as director on 21 Oct 2025
17 Oct 2025OfficersChange to director Candelle Wai Yee Chong on 30 Mar 2023
29 Oct 2025 Incorporation

Memorandum Articles

23 Oct 2025 Resolution

Resolutions

21 Oct 2025 Officers

Termination of Matthew Joseph Barnes as director on 30 Sept 2025

21 Oct 2025 Officers

Appointment of Dr Patrik Foerch as director on 21 Oct 2025

17 Oct 2025 Officers

Change to director Candelle Wai Yee Chong on 30 Mar 2023

Recent Activity

Latest Activity

Memorandum Articles

6 months ago on 29 Oct 2025

Resolutions

6 months ago on 23 Oct 2025

Termination of Matthew Joseph Barnes as director on 30 Sept 2025

6 months ago on 21 Oct 2025

Appointment of Dr Patrik Foerch as director on 21 Oct 2025

6 months ago on 21 Oct 2025

Change to director Candelle Wai Yee Chong on 30 Mar 2023

7 months ago on 17 Oct 2025